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Colorectal cancer is the second most frequent cause of death from
malignancies in the Western world (Hardcastle, 1997). The
survival of colon cancer patients could be substantially improved
by early diagnosis, but many colorectal cancers are detected at a
late stage when surgery cannot cure the disease. At least 40% of
patients with colorectal cancer develop metastases during the
course of their illness (Labianca et al, 1997). Chemotherapy alone
or combined with radiotherapy can be used as a treatment
approach for advanced disease or as an adjuvant therapy to surgery
(Labianca et al, 1997). However, none of these approaches is
highly effective against disseminated colonic cancer (Magnusson
et al, 1995), and the search for new treatment modalities must
continue.
In the past few years, more findings have been accumulated
supporting the role of growth hormone (GH)–insulin-like growth
factor (IGF) I axis in growth of colorectal cancers (Singh and
Rubin, 1993; Pollak et al, 1987). Increased colon epithelial cell
proliferation and a higher risk of developing colonic and other
cancers were demonstrated in patients with acromegaly (Orme et
al, 1998), showing that elevated serum GH and IGF-I levels may
be associated with a higher incidence of colon cancers and various
other malignancies (Pollak et al, 1987, 1989; Pollak and Schally,
1998; Ma et al, 1999). In addition to IGF-I, IGF-II may also play a
major role in progression of colon tumours (Tricoli et al, 1986;
Lahm et al., 1992; Macaulay, 1992). IGF-II mRNA was found to
be overexpressed in about one-third of colon cancers while it was
not detectable in normal colonic mucosa cells (Michell et al,
1997). IGF-II may have a regulatory role in the proliferation and
differentiation of human colonic carcinoma cells (Garrouste et al,
1997). Colon cancer cells also produce specific proteases that
degrade IGF binding proteins (IGFBP) secreted by these cells,
thus decreasing the protective effect of IGFBPs against activation
of the IGF-I receptor (IGF-IR) (Michell et al, 1997).
In view of the involvement of IGF-I and II in growth of various
tumours, we synthesized a series of potent antagonists of growth
hormone-releasing hormone (GH-RH) which interfere with the
GH-RH-GH axis, reduce the secretion of IGF-I by the liver and
decrease the level of IGF-I or -II in tumours (Schally, 1994;
Zarandi et al, 1994, 1997; Schally et al, 1998; Varga et al, 1999).
These analogues inhibit growth of various experimental tumours
(Pinski et al, 1995; Lamharzi et al, 1998; Schally et al, 1998;
Kiaris and Schally, 1999). In the present study, we evaluated the
effects of five GH-RH antagonists on growth of HT-29 human
colon cancers in vivo and in vitro.
MATERIALS AND METHODS
Peptides
GH-RH antagonists [Ibu-Tyr1,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]
hGH-RH(1-28)Agm (MZ-4-71),[PhAc-Tyr1,D-Arg2,Phe(4-Cl)6,Ala15,
Nle27]hGH-RH(1-29)NH2 (MZ-5-186),[PhAc-Tyr1,D-Arg2,Phe(4-
Cl)6,Abu15,Nle27]hGH-RH(1-28)Agm(MZ-5-156),[PhAc-Tyr1,
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D-Arg2,Phe(4-Cl)6,Arg9,Abu15,Nle27,D-Arg29]hGH-RH(1-29)NH2(JV-
1-10), and [PhAc-Tyr1,D-Arg2,Phe(4-Cl)6,Arg9,Abu15,Nle27,D-Arg28,
Har29]hGH-RH(1-29)NH 2 (JV-1-36) were synthesized in our labora-
tory by solid phase methods (Zarandi et al, 1994, 1997; Varga et al,
1999). The peptides were dissolved in 20 ml dimethylsulphoxide
(DMSO) (Sigma, St Louis, MO, USA) and diluted with 10% propy-
lene glycol in water.
Animals and tumours
Male athymic nude mice (Ncr nu/nu), approximately 6 weeks old
on arrival, were obtained from the National Cancer Institute
(Frederick, MD, USA), and maintained under pathogen-limited
conditions. All experiments were approved by the institutional
ACUC and the procedures were essentially in accordance with
UKCCCR guidelines for the welfare of animals in experimental
neoplasia. The methods for culturing of HT-29 cells are described
under in vitro studies. Xenografts were initiated by subcutaneous
(s.c.) injection of 107 cells into the right flank area of nude mice.
Two-mm3 pieces of the developed tumours were further trans-
planted s.c. into the experimental animals.
Experimental protocol
Three in vivo experiments were performed. In Experiment I, the
groups were treated as follows: (1) Control, injection vehicle only;
(2) MZ-4-71, 10 mg twice daily; (3) MZ-5-186, 10 mg twice daily.
Groups 2 and 3 consisted of nine mice, and Group 1 had 15
animals. The treatment was started 15 days after transplantation of
tumours and the mice were injected intraperitonealy (i.p.) twice
daily for 33 days. In Experiment II, the treatment started 7 days
after transplantation of tumours: Group 1 control received vehicle
only; Group 2 MZ-4-71 5 mg twice daily s.c. for 25 days. In
Experiment III, five groups were formed as follows: (1) Control,
vehicle only; (2) MZ-4-71; (3) MZ-5-156;(4) JV-1-10; (5) JV-1-
36. The treatment was initiated 19 days after transplantation. The
mice were injected once daily s.c. with 20 mg of analogues for 42
days. In Experiments II and III the groups consisted of ten animals.
Tumour volume was measured weekly. At the end of the experi-
ments, the mice were sacrificed under Metofane (Malinkrodt 
Vet., Mundelein, IL, USA) anaesthesia by exsanguination. In
Experiment II, two mice in each group received 3 mg of bromo-
deoxyuridine (BrdU) (Sigma, St Louis, MO, USA) i.p. 2 h before
sacrificing.
Histological procedures
Samples were fixed in 10% buffered formalin. Specimens were
embedded in Paraplast (Oxford Labware, St Louis, MO, USA).
Mitotic and apoptotic cells were counted in sections stained with
haematoxylin and eosin and their numbers per 1000 cells were
accepted as the mitotic and apoptotic indices respectively. For
demonstration of the nucleolar organizer region (NOR) in tumour
cell nuclei, the AgNOR method was used as described (Szepeshazi
et al, 1991). The number of AgNOR granules is an indicator of 
cell proliferation. The silver-stained black dots in 50 cells of 
each tumour were counted, and the AgNOR number per cell was
calculated.
BrdU incorporated into cells advancing through S phase of cell
cycle was detected in paraffin-embedded tumour tissue by
immunohistochemistry. Tissue sections on silanated glass slides
were treated with 1% hydrogen peroxide for 15 min and then with
1.0 N hydrochloric acid (HCl) at 60°C for 20 min. Incubation in
the monoclonal anti-BrdU (Sigma) for 60 min at room tempera-
ture (RT) was followed by another incubation in biotin-conjugated
anti-mouse IgG (Vector, Burlingame, CA, USA), 6 mg ml–1, at RT
for 45 min. ABComplex/HRP reagent (Dako, Carpinteria, CA,
USA) was used for 30 min at RT, and the reaction was visualized
with DAB (Sigma). The BrdU containing nuclei in ten high power
microscopic fields were counted and their number per 1000 cells
was accepted as BrdU index.
Electron microscopy
For electron microscopy in Experiment II, 1 mm3 pieces of tumour
tissue were fixed in 2.5% glutaraldehyde for 1 h, postfixed in 
2% OsO4 for 1 h, and embedded into Polybed (Polysciences,
Warrington, PA, USA). The ultrathin sections were counterstained
with uranyl acetate and lead citrate, and studied using a JEM 100
B electron microscope (JEOL, Tokyo, Japan).
IGF-I receptor assay
Receptor binding was characterized using sensitive in vitro ligand
competition assay based on binding of [125I]IGF-I (Amersham
Pharmacia Biotech, Piscataway, NJ, USA) as radioligand to
tumour membrane fractions (Pinski et al, 1995). In brief,
membrane homogenates containing 50–120 mg protein were incu-
bated in triplicate with 50–60 000 cpm radioligand and increasing
concentrations (10–12–10–6 mol l–1) of non-radioactive peptides as
competitors in a total volume of 150 ml of binding buffer. At the
end of the incubations, the reactions were terminated by adding
ice-cold assay buffer to the tubes, and the bound ligand was sepa-
rated from free ligand by centrifugation. Radioactivity in the pellet
of each tube was counted in a gamma counter (Micromedic
Systems, Huntsville, AL, USA). Non-specific binding was
1.4–3.3% of the incubation concentration of [125I]IGF-I in all
tumour samples examined. Protein concentrations were deter-
mined using a Bio-Rad protein assay kit (Bio-Rad Laboratories,
Hercules, CA, USA). The LIGAND PC computerized curve-
fitting program of Munson and Rodbard (1980) was used to eval-
uate types of receptor binding, the maximal binding capacity
(Bmax) of the receptor and the dissociation constant (Kd) values.
Radioimmunoassays for GH, IGF-I and IGF-II
Serum GH was determined using materials provided by Dr AF
Parlow (National Hormone & Pituitary Program, Torrance, CA,
USA): mouse GH 10783B for standard iodination and anti-rat GH-
RIA-5/AFP-411S. The methods used for determination of IGF-I and
IGF-II levels in serum, colon tumour samples and cell culture media
after acid–ethanol cryoprecipitation were described (Lamharzi et al,
1998). Briefly, 100 mg of tumour tissue was homogenized in 1 ml of
homogenization buffer (0.05 M Tris–HCl/0.05 M magnesium chlo-
ride (MgCl2)/30 mg ml–1 bacitracin, pH 7.6) and centrifuged at 2000
g (20 min at 4°C). Protein determination in the supernatant was
performed by using Bio-Rad (Hercules, CA, USA) protein assay kit.
All serum and tumour homogenate samples were extracted by a
modified acid-ethanol cryoprecipitation method. The extracted IGF-
I in serum and tumour samples were measured by RIA using IGF-I
(88-G4 Genentech, San Francisco, CA, USA) standard and antibody
UB2-495 (a gift from LE Underwood and J Van Wyk, University of1726 K Szepeshazi et al
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North Carolina, Chapel Hill, NC, USA) was used at the final dilu-
tion of 1:14 000. IGF-II (Bachem, Torrance, CA, USA) standard and
Amano mAB generated against rat IGF-II 10 mg ml–1 were used at
the final dilution of 1:14 285 (Amano International Enzyme, Troy,
VA, USA).
In vitro studies
The human colon cancer cell line HT-29 was purchased from
ATCC (Rockville, MD, USA). The cells were routinely grown as a
monolayer in McCoy 5A medium (Gibco, Grand Island, NY,
USA) containing 5% fetal bovine serum (FBS) and antibiotics and
antimycotics. HT-29 cells were seeded into 96-well microplates
and cultured for 24 h. IGF-I (10 and 25 ng ml–1), IGF-II (500 and
800 ng ml–1), GH (5 and 25 ng ml–1) and MZ-5-156 (3 ´ 10–7 and 
3  ´ 10–6 M) were added to the medium (t0). Controls received
medium only. After 66 or 90 h, in vitro cell growth was estimated
using the crystal violet assay (Bernhardt et al, 1992). The OD at
600 nm of each well was measured using a Beckman (Palo Alto,
CA, USA) plate reader. Then, %T/C was calculated, where
T = optical density (OD600 nm) of treated cultures and C = OD600 nm
of control cultures ´ 100 (t0 = OD600 at start of experiment).
HT-29 cells were also cultured in serum-free medium containing
McCoy 5A, 0.5% bovine serum albumin (BSA), 1 mM pyruvate, 50
mg ml–1 transferrin and 1 mM FeSO4. The IGF-I and IGF-II concen-
tration of the medium was measured by radioimmunoassay (RIA),
and the effect of 3 ´ 10–7 and 3 ´ 10–6 M of
MZ-5-156, 25 ng ml–1 of GH, 25 ng ml–1 of IGF-I, 800 ng ml–1 of
IGF-II, on cell proliferation was studied using the crystal violet assay.
For measurement of IGF-I and IGF-II in media of HT-29 cells,
samples were taken before seeding of cells (base medium) and 
24 h after seeding, immediately before treatments (t0). The
peptides were added to the media at concentrations described
above (8 wells for each), the controls receiving medium only.
Samples were taken 66 h and 138 h after addition of the peptides
(t1 and t2 respectively). The experiment was done in duplicate.
IGF-I and IGF-II mRNA expression in HT-29 cells and
HT-29 tumours
HT-29 cells were harvested as described above 4 h after addition
of MZ-5-156 to the medium. Total RNA was extracted from
control and treated cells and tumour tissue samples as described
(Lamharzi et al, 1998).
The methods of reverse transcription (RT) and polymerase chain
reaction (PCR) amplification were also reported earlier (Lamharzi
et al, 1998). Three micrograms of total RNA was reverse-tran-
scribed using the RT-PCR Kit (Stratagene, La Jolla, CA, USA)
according to manufacturer’s instructions. PCRs for IGF-I, IGF-II
and b-actin (internal control) were carried out in a final volume of
100 ml containing 10 mM Tris (pH 8.8), 50 mM potassium chloride,
1.5 mM MgCl2, 0.2 mM of each dNTP, sense and antisense primers
at a concentration of 0.12 mM each, and 2.5 U Taq 2000 poly-
merase (Stratagene). The primers for human IGF-I were
(Lamharzi et al, 1998): 5¢-ACATCTCCCATCTCTCTGGATTTC-
CTTTTGC-3¢ (sense) and 5¢-CCCTCTACTTGCGTTCTTCA-
AATGTACTTCC-3¢ (antisense). The primers for human IGF-II
were: 5¢-AGTCGATGCTGGTGCTTCTCACCTTCTTGGC-3¢
(sense) and 5¢-TGCGGCAGTTTTGCTCACTTCCGATTGC-
TGG-3¢ (antisense). The primers for human b-actin were: 5¢-
TCATGAAGTGTGACGTGGAC-3¢ (sense) and 5¢-ACCGACTG-
CTGTCACCTTCA-3¢ (antisense). PCR was performed in a
GeneAmp PCR System 2400 (Perkin-Elmer, Norwalk, CT, USA)
using a step programme of 35 cycles of 95°C for 15 s and 60°C for
30 s for IGF-I and IGF-II. For b-actin, a step programme of 32
cycles of 94°C for 45 s, 60°C for 45 s and 72°C for 45 s was used.
The reaction was finished with a final step of 72°C for 10 min.
Negative controls containing RNA were used to confirm that the
samples were not contaminated with genomic DNA. Ten
microlitres of the PCR products were separated on 1.8% agarose
gel and visualized by ethidium bromide on a UV transilluminator.
The banded areas were scanned and quantified using an imaging
densitometer (Bio-Rad).
Table 1 Effect of treatment with various GH-RH antagonists on tumour volume and weight, IGF-II concentrations and IGF-II mRNA expression in HT-29
human colon cancers growing in nude mice
Groups IGF-II in tumours
Tumour volume (mm3) Tumour Concentrations mRNA
weights (pg 100 mg–1 expression
Initial Final (g) protein) (ratio to b-actin)
Experiment I (dose 10 mg twice daily i.p.)
1. Control 116 ± 31 5386 ± 1120 5.68 ± 1.25
2. MZ-4-71 127 ± 57 2985 ± 726a 3.63 ± 0.97
3. MZ-5-186 122 ± 71 3657 ± 808 4.91 ± 0.94
Experiment II (Dose 5 mg twice daily s.c.)
1. Control 22 ± 7 9514 ± 1809 10.27 ± 2.04 408 ± 13
2. MZ-4-71 23 ± 4 5402 ± 1331a 7.53 ± 1.81 264 ± 10a
Experiment III (dose 20 mg day–1 s.c.)
1. Control 70 ± 31 2117 ± 751 2.36 ± 0.84 353 ± 8 0.55 ± 0.09
2. MZ-4-71 64 ± 18 1953 ± 400 2.19 ± 0.46 280 ± 10 0.50 ± 0.13
3. MZ-5-156 57 ± 18 908 ± 195a 1.01 ± 0.17a 228 ± 24a 0.31 ± 0.05a
4. JV-1-10 67 ± 29 1194 ± 506a 1.38 ± 0.58a 297 ± 16 NA
5. JV-1-36 45 ± 12 890 ± 322a 1.35 ± 0.48a 238 ± 35a 0.20 ± 0.03a
Values are means ± s.e.m, aP < 0.05 vs control. NA = no data because of a technical problem. Experiments I and II were done in 1995.Statistical methods
Statistical analyses of the data were performed using Duncan’s
new multiple range test and Student’s two-tailed t-test. All
P-values are based on two-sided hypothesis testing.
RESULTS
Effect of GH-RH antagonists on colon cancers in vivo
At the end of Experiments I and II, the average tumour volume 
in the groups receiving MZ-4-71 was reduced by about 45% 
(P < 0.05) compared to the control groups (Figure 1 A,B). Tumour
weights were also decreased in the same groups in both experi-
ments, however, the differences from control were not significant
statistically (Table 1). In Experiment III, daily treatment with 
20 mg day–1 of MZ-5-156 or JV-1-36 strongly inhibited growth of
tumours, reducing tumour volume by 57% and 58% and tumour
weights by 57% and 43% respectively. The effect of JV-1-10 was
weaker, and treatment with MZ-4-71 resulted only in a non-signif-
icant inhibition (Figure 1C). Tumour volume and weight data are
shown in Table 1.
Histological studies demonstrated that treatment with MZ-4-71
significantly reduced the number of mitotic cells and AgNOR
counts in tumours in Experiment I and II (Table 2). In Experiment
II, the number of cells incorporating BrdU was reduced by 50% in
the group treated with MZ-4-71. AgNOR numbers and BrdU
indices of individual tumours showed a good correlation (r =
0.75). In Experiment III, mitotic indices were lower in groups
treated with GH-RH antagonist, and AgNORs were reduced
significantly by all therapies. Apoptotic cells were identified by
their characteristic morphology in histological slides stained with
HE. Parallel electron microscopic investigations were helpful in
recognizing apoptotic cells (Figure 2). The number of apoptotic
cells was increased by MZ-4-71 in Experiment I and II, and by
MZ-5-156 in Experiment III. The ratio of apoptotic to mitotic
indices was significantly higher in the groups receiving MZ-4-71,
MZ-5-156 and JV-1-36. The quantitative histological data are
shown in Table 2.
Receptor studies
In the control group of Experiment II, radiolabelled IGF-I was
bound to a single class of high affinity (Kd = 0.92 ± 0.04 nM), low
capacity (Bmax = 129.7 ± 16.6 fmol mg–1 membrane protein)
binding sites (Figure 3). Treatment with GH-RH antagonist MZ-4-
71 did not affect significantly the affinity (Kd = 0.83 ± 0.10 nM), or
capacity (Bmax = 135.9 ± 32.4 fmol mg–1 protein) of the receptors
for IGF-I in HT-29 tumour membrane fractions.
IGF-I and IGF-II concentrations in tumour tissue
IGF-I concentration in the control tumours of Experiment II was
219 ± 4.2 pg 100 mg–1 protein and 139 ± 12.7 pg 100 mg–1 protein
in the cancers treated with MZ-4-71. The difference was not
significant statistically. IGF-II levels in HT-29 cancers were
analysed in Experiments II and III. The results are shown in Table
1. IGF-II concentrations were decreased in the tumours treated
with MZ-4-71 in Experiment II, and after therapy with MZ-5-156
and JV-1-36 in Experiment III.
Expression of IGF-I and IGF-II mRNA in HT-29 cells and
cancers
IGF-II mRNA in HT-29 cancers was expressed as IGF-II b-actin–1
ratios. The results are shown in Table 1. Treatment with MZ-5-156
and JV-1-36 in Experiment III reduced IGF-II mRNA in colon
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Figure 1 Tumour volume changes of HT-29 human colon cancer xenografts
in nude mice in Experiments I (A), II (B) and III (C). The mice were treated
with daily injections of GH-RH antagonists i.p. (Experiment I) or s.c.
(Experiment II and III). *P < 0.05. The vertical bars show s.e.m. of selected
groupscancers (P < 0.05). A representative gel is shown in Figure 4.
IGF-I mRNA could not be detected in HT-29 cancers.
Serum GH, IGF-I and IGF-II levels
Levels of GH, IGF-I and IGF-II in serum were determined in
Experiment II and III. In Experiment III, treatment with MZ-5-156
decreased serum IGF-I by 26%, other analogues did not affect
serum IGF-I levels (data not shown). None of the analogues
produced significant changes of serum IGF-II and GH.
In vitro studies
Exogenous IGF-I at 10 and 25 ng ml–1 and IGF-II at 500 and 
800 ng ml–1 concentrations enhanced growth of HT-29 cells
cultured in serum containing medium, and the stimulatory effects
of IGFs were more evident at 66 h (Figure 5). Addition of MZ-5-
156 to the medium at 3 ´ 10–6 M concentration inhibited prolifera-
tion of the colon cancer cells (Figure 5), the effects being
significant after 114 h.
HT-29 cells were also grown in serum-free medium. The addi-
tion of 25 ng ml–1 of IGF-I or 800 ng ml–1 of IGF-II significantly
increased cell growth after 66 h (P < 0.05). Slight stimulatory
effects (P < 0.05) were also seen after 114 h. MZ-5-156 at 3 ´ 10–6
concentration inhibited proliferation of the colon cancer cells at
both time points (Figure 6).
IGF-I concentration in serum-free medium was not increased
after seeding of HT-29 cells, and was not influenced by addition of
MZ-5-156 or GH. However, IGF-II levels in serum-free medium
showed dramatic increases in relation to the time of incubation
after seeding of HT-29 cells, demonstrating that the cells secrete
IGF-II into the medium. Adding of MZ-5-156 to the medium,
dose-dependently reduced IGF-II levels at 138 h culture time to
about 60% of control values (Figure 7).
DISCUSSION
IGF-I is the mediator of the normal growth promoting effect of
GH, and operates by activating the IGF-I receptor (IGF-I R)
(Westley and May, 1995). The IGF-I R is required for cancer cell
proliferation by establishing and maintaining the transformed
1728 K Szepeshazi et al
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Table 2 Effect of treatment with various GH-RH antagonists on some histological characteristics of HT-29 human colon cancers growing in nude mice
Groups Mitotic index Apoptotic index Ratio of apoptotic Number of BrdU index
to mitotic indices AgNORs cell–1
Experiment I dose (see Table 1)
1. Control 11.2 ± 1.4 7.3 ± 1.7 0.72 ± 0.21 7.20 ± 0.23
2. MZ-4-71 6.9 ± 1.1a 10.0 ± 1.1 1.56 ± 0.27a 6.20 ± 0.39a
3. MZ-5-186 8.0 ± 1.7 6.1 ± 1.1 0.86 ± 0.20 6.40 ± 0.29
Experiment II dose (see Table 1)
1. Control 16.5 ± 1.2 5.4 ± 0.6 0.33 ± 0.04 6.85 ± 0.16 140.0 ± 28.4
2. MZ-4-71 12.0 ± 1.3b 10.0 ± 0.7b 1.02 ± 0.17b 5.60 ± 0.11b 69.8 ± 7.4a
Experiment III dose (see Table 1)
1. Control 14.1 ± 1.2 7.3 ± 1.3 0.57 ± 0.14 6.99 ± 0.15
2. MZ-4-71 12.7 ± 1.2 8.9 ± 0.9 0.73 ± 0.09 6.16 ± 0.10b
3. MZ-5-156 9.1 ± 1.0a 11.4 ± 1.3a 1.40 ± 0.23a 5.63 ± 0.10b
4. JV-1-10 10.6 ± 1.8 8.2 ± 1.0 0.87 ± 0.12 6.25 ± 0.13b
5. JV-1-36 7.4 ± 1.5b 9.4 ± 1.1 1.33 ± 0.17a 5.77 ± 0.15b
Values are means ± s.e.m., aP < 0.05, bP < 0.01.
Figure 2 Electron microscopic picture of an apoptotic cell showing dense
shrunken nucleus and condensed cytoplasmic organelles in a HT-29 tumour
after treatment with MZ-4-71 in Experiment II (Bar = 5 mm)
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Figure 3 Representative example of Scatchard plots of [125I]IGF-I binding to
the membrane fraction isolated from HT-29 human colon cancers. Specific
binding was determined as described. Each point represents mean of
triplicate determinationsphenotype (Baserga, 1995). Overexpression of IGF-IRs is suffi-
cient for cell transformation and increased cell proliferation
(Blakesley et al, 1997). Genetically engineered dominant negative
human IGF-IR induces apoptosis and inhibits cell growth and
tumorigenesis (D’Ambrosio et al, 1996).
The IGF-IR is also target for IGF-II. IGF-II has an important
role in progression of various tumours (Singh and Rubin, 1993;
Toretsky and Helman, 1996; Schally et al, 1998). Stimulation of
IGF-IR by IGF-II through autocrine or paracrine pathways
(Toretsky and Helman, 1996) may allow cancer cells to maintain
unregulated growth and resist programmed cell death (Singleton et
al, 1996).
More and more findings are accumulating about the role of IGF-
II in progression of colorectal cancers (Tricoli et al, 1986; Lahm 
et al, 1992, 1996; Toretsky and Helman, 1996). IGF-II levels are
higher in blood of patients with colorectal cancer compared with
matching normal population, but IGF-I concentrations were found
normal (elAtiq et al, 1994). IGF-II was found to be a growth factor
for some colorectal cancer cell lines (Lahm et al, 1992). IGF-I
receptor was expressed in all 12 colon cancer cell lines tested, and
antibody to the IGF-IR inhibited growth of these lines (Lahm et al,
1996). Williams et al (1992) also demonstrated the significance of
IGF-I in development of colon cancers, and the growth of several
colon cancer cell lines in serum-free medium was stimulated by
IGF-I.
In view of the essential role of IGFs in tumour progression, the
regulatory mechanisms need to be clarified. According to the clas-
sical hypotheses, IGF-I may function as a circulating hormone
secreted by the liver in response to GH (Jones and Clemmons,
1995). GH may also regulate local production of IGF-I in other
GH-RH antagonists inhibit colon cancer 1729
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Figure 4 RT-PCR analysis of human IGF-II and b-actin mRNA expression
in HT-29 colon cancers. The sizes of expected PCR products were 538 and
459 for hIGF-II and hb-actin respectively. Lanes: M: molecular weight marker
(Sigma); 1–4: IGF-II; 5–8: b-actin. Lanes 1 and 5: control, 2 and 6: MZ-5-156,
3 and 7: MZ-4-71, 4 and 8: JV-1-36
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Figure 5 Effect of IGF-I, IGF-II and GH-RH antagonist MZ-5-156 on growth
of HT-29 human colon cancer cells cultured in serum-containing medium 66
and 114 h after addition of the peptides. Growth was measured by crystal
violet assay and expressed as percentage of control. *P < 0.05 vs control
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Figure 6 Effect of IGF-I, IGF-II, GH and GH-RH antagonist MZ-5-156 on
growth of HT-29 human colon cancer cells cultured in serum-free medium 66
and 114 h after addition of the peptides. Growth was measured by crystal
violet assay and expressed as percentage of control. *P < 0.05 vs control
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Figure 7 Concentration of IGF-I and IGF-II in serum-free medium 66 and
138 h after addition of GH-RH antagonist MZ-5-156 or GH (at 0 h). HT-29
cells were seeded 24 h before addition of peptides. Control cultures received
serum-free medium only. All IGF-II levels were higher at 66 h and 138 h than
those at 0 h (P < 0.001). *P < 0.01 vs control at 138 h1730 K Szepeshazi et al
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tissues. However, the regulation of IGF-II is less clear and involve-
ment of GH in IGF-II production is controversial (Jones and
Clemmons, 1995; Schally et al, 1998). The effects of IGFs are also
regulated by IGF-binding proteins (IGFBP). IGFs bind to these
proteins with higher affinity than to the IGF-I receptor and thus
IGFBPs can modulate their bioavailability for tissues (Mohan and
Baylink, 1996; Toretsky and Helman, 1996).
In the present study, various GH-RH antagonists inhibited
growth of HT-29 colon cancer xenografts with variable efficacy.
MZ-5-186 and JV-1-10 had only a small effect. MZ-4-71 was more
powerful when it was given twice daily, while MZ-5-156 and JV-
1-36 caused the strongest inhibition. These differences in activity
can be explained by different stability of the compounds in circula-
tion (Zarandi et al, 1994, 1997; Kovacs et al, 1996, 1997). It was
demonstrated previously that MZ-5-156 has a longer life-span in
blood than MZ-4-71 (Kovacs et al, 1996, 1997), thus given once a
day, MZ-4-71 is less effective than when administered twice daily.
Histological analysis demonstrated that decreased cell prolifera-
tion and increased apoptosis both contributed to tumour inhibition
by the GH-RH antagonists. IGFs and IGF-IR have special anti-
apoptotic activity. In our studies, the decrease in IGF-II activity
caused by the GH-RH antagonists resulted in a restoration of apop-
totic process that contributed to inhibition of tumour growth.
The mechanism of action of the GH-RH antagonists is not fully
clarified, but our present in vivo and in vitro studies shed addi-
tional light on the tumour inhibitory effects of these peptides.
There were no changes in IGF-I levels in blood showing that
tumour inhibition can occur without a decrease in the systemic
supply of hepatic IGF-I. GH-RH antagonists did not affect binding
characteristics of IGFRs or IGF-I concentration in the tumours. In
contrast, IGF-II levels were significantly decreased in the HT-29
cancers of mice treated with MZ-4-71, MZ-5-156 or JV-1-36, and
mRNA for IGF-II was also reduced in the same tumours.
In vitro studies showed that HT-29 cells produce and secrete
IGF-II but not IGF-I. These findings are in accord with the results
of other studies (Lobie et al, 1990; Singh and Rubin, 1993; elAtiq
et al, 1994). Exogenous IGF-I and IGF-II enhanced growth of HT-
29 cells in our experiments. Lahm et al (1992, 1996) reported
similar results, whereas others could not detect any effects of
exogenous IGFs on colon cancer cell growth (Singh and Rubin,
1993). In view of the key role of IGF-II in cancers and the fact that
IGF-II acts through the IGF-I receptor, either of these may become
targets for new therapeutic approaches to colorectal cancer.
GH-RH antagonists might act by inhibiting GH/IGF-I axis, or
may have a direct effect on tumours. The peptide receptors in
tumours that respond to GH-RH antagonists appear to be different
from the pituitary GH-RH receptors (unpublished data). GH-RH is
a member of the family of peptides that includes vasoactive
intestinal peptide (VIP), glucagon, secretin, gastric inhibitory
peptide, and pituitary adenylate cyclase-activating peptide
(PACAP) (reviewed in Lamharzi et al, 1998). These peptides
demonstrate significant amino acid sequence homology. The
human and rat GH-RH receptors are homologous to secretin and
VIP receptor proteins (Mayo, 1992). Thus, GH-RH and its
analogues may act through other related receptors. VIP receptors
and PACAP receptors were detected in various gastrointestinal
tumours (Reubi, 1995; Raderer et al, 1998) and also in human
colon cancer cell lines including HT-29 cancers (Lelievre et al,
1998). Antagonistic analogues of GH-RH suppress the stimulatory
effects not only of GH-RH but also of VIP on the cAMP produc-
tion of various cancer cells (Csernus et al, 1999). In our in vitro
studies, GH-RH antagonist MZ-5-156 inhibited the proliferation
of HT-29 cells growing in normal or serum-free medium. MZ-5-
156 also decreased the secretion of IGF-II by HT-29 cells into the
medium, thus suggesting a receptor-based mechanism for tumour
growth inhibition. Since the GH-RH antagonist exerted these
effects in vitro, this reinforces the hypothesis of direct action of
MZ-5-156 on HT-29 cells.
Investigations are in progress to identify the peptide receptors
that bind GH-RH antagonists in various tumours. It is probable
that these receptors belong to the common neuropeptide receptor
family (Mayo, 1992) that can bind peptides with similar structures
such as VIP or GH-RH. After a future identification of binding
sites for GH-RH analogues some intracellular pathways of their
action may be clarified. The potent anti-tumour activity of GH-RH
antagonists supports the merit of further investigation of their
mechanisms of action and the development of more active and
stable analogues.
Our work indicates that GH-RH antagonists by virtue of
inhibiting IGF-I and/or II may offer new approaches to treatment
of colorectal cancer and other malignancies.
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